Isolated REM Sleep Behavior Disorder (iRBD) is the strongest prodromal marker for α-synucleinopathies. Overt α-synucleinopathies and aging share several mechanisms, but this relationship has been poorly investigated in prodromal phases. Using DNA methylation-based epigenetic clocks, we measured biological aging in videopolysomnography confirmed iRBD patients, videopolysomnography-negative and population-based controls. We found that iRBDs tended to be epigenetically older than controls, suggesting that accelerated aging characterizes prodromal neurodegeneration.

Epigenetic clocks suggest accelerated aging in patients with isolated REM Sleep Behavior Disorder / Baldelli L.; Pirazzini C.; Sambati L.; Ravaioli F.; Gentilini D.; Calandra Buonaura G.; Guaraldi P.; Franceschi C.; Cortelli P.; Garagnani P.; Bacalini M.G.; Provini F.. - In: NPJ PARKINSON'S DISEASE. - ISSN 2373-8057. - ELETTRONICO. - 9:1(2023), pp. 48.48-48.48. [10.1038/s41531-023-00492-2]

Epigenetic clocks suggest accelerated aging in patients with isolated REM Sleep Behavior Disorder

Baldelli L.;Pirazzini C.;Sambati L.;Ravaioli F.;Calandra Buonaura G.;Guaraldi P.;Franceschi C.;Cortelli P.;Garagnani P.;Bacalini M. G.;Provini F.
2023

Abstract

Isolated REM Sleep Behavior Disorder (iRBD) is the strongest prodromal marker for α-synucleinopathies. Overt α-synucleinopathies and aging share several mechanisms, but this relationship has been poorly investigated in prodromal phases. Using DNA methylation-based epigenetic clocks, we measured biological aging in videopolysomnography confirmed iRBD patients, videopolysomnography-negative and population-based controls. We found that iRBDs tended to be epigenetically older than controls, suggesting that accelerated aging characterizes prodromal neurodegeneration.
2023
Epigenetic clocks suggest accelerated aging in patients with isolated REM Sleep Behavior Disorder / Baldelli L.; Pirazzini C.; Sambati L.; Ravaioli F.; Gentilini D.; Calandra Buonaura G.; Guaraldi P.; Franceschi C.; Cortelli P.; Garagnani P.; Bacalini M.G.; Provini F.. - In: NPJ PARKINSON'S DISEASE. - ISSN 2373-8057. - ELETTRONICO. - 9:1(2023), pp. 48.48-48.48. [10.1038/s41531-023-00492-2]
Baldelli L.; Pirazzini C.; Sambati L.; Ravaioli F.; Gentilini D.; Calandra Buonaura G.; Guaraldi P.; Franceschi C.; Cortelli P.; Garagnani P.; Bacalini M.G.; Provini F.
File in questo prodotto:
File Dimensione Formato  
Baldelli_NPJ_2023.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 698.97 kB
Formato Adobe PDF
698.97 kB Adobe PDF Visualizza/Apri
41531_2023_492_MOESM1_ESM.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 324.88 kB
Formato Adobe PDF
324.88 kB Adobe PDF Visualizza/Apri
41531_2023_492_MOESM2_ESM.pdf

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 2.49 MB
Formato Adobe PDF
2.49 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/955137
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact